STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the appointment of Professor Paul Workman to its Board. This appointment continues STORM’s evolution of its management and advisory networks as it fulfils its ambition to become the leading therapeutics company in RNA epigenetic modulation.
CEO of STORM Therapeutics, Keith Blundy commented on the appointment: “I am pleased to
welcome Paul asIndependent Director to STORM’s board. Paul brings a wealth of experience in cancer
biology and drug discovery, in addition to the translational expertise of moving emerging biology to
therapeutic applications through his experience of leading a world class cancer institute and being a
founder of companies such as Piramed. We look forward to Paul’s input on development and
positioning of STORM’s emerging RNA epigenetics platform and programmes.”
Professor Paul Workman, Chief Executive and President of The Institute of Cancer Research, London,
said: “I am delighted to be joining the board of STORM and working with the company in this exploding
area of biology. RNA epigenetic modulation is an exciting area of science with real potential to deliver
new targeted cancer therapies. I look forward to working with the board to help guide STORM’s
innovative research programmes, adding my experience from drug discovery in academia, pharma
and biotech.”
For further information:
STORM Therapeutics Ltd
Keith Blundy
T: +44 (0)1223 804174
info@stormtherapeutics.com
Optimum Strategic Communications
Mary Clark, Hollie Vile
Tel: +44 203 714 1787
storm@optimumcomms.com
NOTES TO EDITORS
About STORM
STORM Therapeutics is a University of Cambridge spin-out, translating the groundbreaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases. It is the only company currently tackling disease through modulating RNA modifying enzymes and is developing a unique platform to address these enzyme classes, including RNA methyltransferases. STORM is backed by blue chip investors Cambridge Innovation Capital, M Ventures, Pfizer Ventures and Touchstone Innovations, who share the founders’ ambitions to build a world-leading company in the field. The company raised its series A funding in June 2016 and occupies modern, well-equipped laboratories on the Babraham Research Campus near Cambridge, UK.
About Professor Workman
Professor Paul Workman FMedSci, FRS is Chief Executive and President of The Institute of Cancer Research (ICR). He is Harrap Professor of Pharmacology and Therapeutics at the ICR, as well as the former Head of the Division of Cancer Therapeutics and former Director of the Cancer Research UK Cancer Therapeutics Unit from 1997-2016 - a period of 18 years. A leader in the field of molecularly targeted cancer drugs, he is a Fellow of the Royal Society, Academy of Medical Sciences, the Royal Society of Medicine, the Royal Society of Chemistry and the Royal Society of Biology and is a Cancer Research UK Life Fellow. Paul's research focus is the discovery and development of cancer drugs that exploit our knowledge of the cancer genome and cancer biology and his passion is personalised medicine. He has won numerous awards that are listed in his Biography.
